Meiji Holdings Co., Ltd.
MEJHF
Other OTC20.25
USD
- -
- -
CIK
0001558812
ISIN
JP3918000005
Return %
Stock
S&P500
1Y
0.01
26.99
3Y
-16.31
77.19
5Y
-35.65
79.08
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Katsunari Matsuda
- Full Time Employees
- 17,270
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 2-4-16, Kyobashi Tokyo Japan 104-0031
- IPO Date
- Feb 2, 2010
- CIK
- 0001558812
- Website
- meiji.com
- Similar Companies
- Business
- Meiji Holdings Co., Ltd. Meiji Holdings Co., Ltd. is a Japan-based pure holding company that oversees subsidiaries engaged in the food and pharmaceuticals sectors; it manages the manufacture and sale of dairy products including yogurt, milk, cheese, butter, ice cream and beverages; confectionery such as chocolate, gummy candy, gum and snacks; nutritional products like protein supplements, infant formula, health foods and sports nutrition; as well as pharmaceuticals encompassing ethical drugs for infectious diseases, central nervous system disorders and immune inflammatory conditions, vaccines, blood plasma products, generic drugs, animal health products and contract manufacturing services. Headquartered in Tokyo at 2-4-16 Kyobashi, Chuo-ku, the company was established on April 1, 2009, through the integration of Meiji Seika and Meiji Dairies, with roots tracing back to 1916; its key subsidiaries include Meiji Co., Ltd. for food operations, Meiji Seika Pharma Co., Ltd. for pharmaceuticals and KM Biologics Co., Ltd. for biologics and vaccines, serving domestic and international markets across Asia, Europe and the Americas with approximately 17,270 employees as of March 2024. The group operates through two primary segments, with the food business accounting for around 81% of sales and focusing on wellness-oriented products utilizing lactic acid bacteria, milk and cacao research; the pharmaceuticals segment, representing 19% of sales, emphasizes infectious disease countermeasures including antibacterial drugs and next-generation mRNA vaccines like KOSTAIVE. Meiji Holdings pursues food-pharmaceutical synergies and open innovation under its 2026 Medium-Term Business Plan, targeting mid-to-high single-digit operating income growth, 20% overseas sales ratio and ROE of 10%, while advancing sustainability initiatives such as sustainable cacao procurement via Meiji Cocoa Support and dairy farming support. Recent strategic changes include a January 2024 licensing agreement with Seqirus Inc. for the ARCT-154 self-amplifying mRNA COVID-19 vaccine and future variants in Japan; the July 2018 acquisition of KM Biologics Co., Ltd.; and a November 2025 board resolution to transfer its KM Biologics shares to Meiji Seika Pharma via absorption-type company split effective January 2026 to enhance pharmaceutical integration, R&D, manufacturing and global expansion in infectious diseases.